antibiotic resistance

The firm beat the consensus Wall Street estimate on the top line but fell short of the estimate on the bottom line.

The Mountain View, California-based firm will first offer the system for evaluation and clinical use in France and the United Kingdom.

The company first submitted for 510(k) clearance last year and has received two additional information requests from the agency.

The option was exercised under a multiyear contract between T2 Bio and BARDA valued at a total of $69 million if all options are exercised.

The project, coordinated by Jena University Hospital and expected to run for five years, aims to address resistance mechanisms in Gram-negative pathogens.

The loan will help fund Scope's development of its PCR One point-of-care molecular diagnostic instrument and related respiratory virus panel.

The PCR diagnostic device is a palm-size, single-use, disposable device that detects N. gonorrhoeae and determines if it's susceptible to an antibiotic.